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ABSTRACT  
Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved for 
the treatment of castration-resistant prostate cancer (CRPC) in chemotherapy-naïve as well as in 
patients previously exposed to chemotherapy. However, resistance to enzalutamide and 
enzalutamide withdrawal syndrome have been reported. Thus, reliable and integrated preclinical 
models are required to elucidate the mechanisms of resistance and to assess therapeutic settings that 
may delay or prevent the onset of resistance.  
In this study, the prostate cancer (PCa) multistage murine model TRAMP and TRAMP-derived 
cells have been used to extensively characterize in vitro and in vivo the response and resistance to 
enzalutamide. The therapeutic profile as well as the resistance onset were characterized and a 
multiscale stochastic mathematical model was proposed to link the in vitro and in vivo evolution of 
PCa. The model showed that all therapeutic strategies that use enzalutamide result in the onset of 
resistance. The model also showed that combination therapies can delay the onset of resistance to 
enzalutamide, and in the best scenario, can eliminate the disease. These results set the basis for the 
exploitation of this "TRAMP-based platform" to test novel therapeutic approaches and build further 
mathematical models of combination therapies to treat PCa and CRPC. 
 
Significance:     
Merging mathematical modeling with experimental data, this study presents the "TRAMP-based 
platform" as a novel experimental tool to study the in vitro and in vivo evolution of prostate cancer 





Prostate cancer (PCa) represents a leading cause of death in the male population with around 
180,890 new cases and 26,120 estimated deaths in the United States in 2016 [1].  
Prostate development and PCa are androgen-dependent physiological and pathological contexts 
where Androgen Receptor (AR), acting as a ligand-dependent transcription factor [2], can initiate 
expression of genes controlling the balance between cell differentiation and proliferation. The 
prostatic epithelial AR signaling axis is a key regulator for the functionality, survival and 
differentiation of normal prostate [3]. In contrast, during carcinogenesis and prostate 
transformation, AR axis shifts toward a proliferative and tumor promoting gene set [4] due to 
aberrant activation by androgens, AR mutations/amplification, or changes in co-regulators 
interactions as well as signal pathways that activate AR activity at very low levels of androgen [5]. 
It is therefore crucial to inhibit androgen signaling either by depriving the tumor from androgens or 
by blocking the receptor activity.  
To date, the androgen deprivation therapy (ADT) represents the standard care for the treatment of 
advanced PCa. Even though the suppression of androgens/AR functions is an effective treatment for 
most prostate cancer patients [6], clinical studies show that most prostate tumors regrow after a 
median duration of response of 12–24 months under continuous ADT and progress to what is 
termed as castration-resistance prostate cancer (CRPC) with an average survival of 2-3 years [7]. 
Although CRPC should be no longer controlled by androgen suppression, the clinical development 
of second-generation AR antagonists, which display higher affinity for the receptor as well as good 
efficacy as AR signaling inhibitor, has proven that the AR remains a critical oncogene in CRPC [8].  
Indeed, preclinical evidence suggests that AR overexpression confers resistance to ADT in vitro [9], 
and that intra-tumoral levels of androgens are increased in patients with progressive PCa [10].  
Enzalutamide (MDV3100, Xtandi®) is a non-steroidal second-generation AR inhibitor that 
competitively binds to the ligand-binding domain of the AR with higher affinity than conventional 
anti-androgens, impairs AR translocation to the nucleus, recruitment of cofactors, and binding to 
DNA [11]. Enzalutamide has been associated with significant benefits in terms of prolonged 
survival in CRPC [12], although patients eventually experience disease progression. The 
mechanisms that underlie this resistance have not yet been clarified, and could be either dependent 
or independent from AR activity [13]. 
Many preclinical models of prostate cancer, mainly consisting of human or murine cell lines, are 
routinely used to assess the effect of different therapeutic approaches. However, none of these 
models fully recapitulates all the parameters of PCa progression in human disease, including 
formation of initial hyperplasia, intraepithelial neoplasia (PIN), adenocarcinoma, metastasis and 
recurrence from androgen deprivation therapy [14]. All these features of tumor onset and 
progression have been described in TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) 
mice [15], a multistage prostate cancer model where the androgen-responsive rat probasin (rPB) 
gene promoter drives the prostate specific expression of the SV40-Tag. Prostate cancer in TRAMP 
mice mimics the development of human PCa, and transiently regresses following androgen 
withdrawal (e.g., by castration), but relapses as fatal androgen-independent PCa similar to what is 
commonly observed in men [16].  
In this study, we characterized the response of TRAMP mouse as well as of TRAMP mouse-derived 
TRAMP-C2 cells to enzalutamide in vitro and in vivo, by generating in vitro enzalutamide-resistant 
TRAMP-C2 cells and by defining in vivo the therapeutic and relapse profile of enzalutamide in the 
multistage TRAMP model. The experimental evidence, together with the collected data, allowed the 
realization of a mathematical model that, for the first time, well describes the response and relapse 
to enzalutamide during tumor progression.  The model suggested that resistant cells have a higher 
fitness than sensitive cells, and that the slow growth of resistant cells observed in vitro is 
compensated by their higher efficiency to grow under oxygen and glucose deprived conditions 
when in vivo. Finally, in silico experiments revealed that, regardless of time and/or treatment 
schedule, resistant cells take over, and combination treatments are required to delay tumor relapse.  
 
 
MATERIALS AND METHODS  
Cell lines. Murine prostate adenocarcinoma TRAMP-C2 cells were obtained from ATCC-LGC 
Standards Repository (ATCC number CRL-2731) and maintained in DMEM supplemented with 
10% heat inactivated fetal calf serum (FCS), 10 mM HEPES Buffer, 0.5 mM 2-mercaptoethanol, 
2.0 mM glutamine, 5 mg/L bovine insulin (Sigma-Aldrich) and 10 nM DHT. Cells were kept at low 
passage, returning to original frozen stocks every 3 to 4 months, and tested regularly for 
Mycoplasma negativity and morphology. Enzalutamide-resistant TRAMP-C2 cell line was 
generated culturing parental cells under increasing concentrations of enzalutamide (from 3µM up to 
40µM) and maintaining the highest concentration up to 6 months. To verify the acquisition of 
resistant phenotype three parameters have been considered: 1) sensitivity to an acute treatment with 
enzalutamide via flow cytometry; 2) gene expression of castration resistant state biomarkers via 
PCR analysis; 3) metabolomics and extracellular flux analyses via NMR spectroscopy and Seahorse 
platform (see Supplementary Material and Methods). To exclude senescence related effects, a 
parental cell line, has been cultured in parallel with the same passage number to test the above 
parameters.  
 
Cell proliferation assay. TRAMP-C2 cells were seeded in 48-well plates at 25,000 cells/cm2 and 
treated with increasing concentrations (5-100µM) of enzalutamide (MDV3100 - Selleckchem). 
Cells were cultured under appropriate conditions for 96 hours. Propidium iodide staining 
(Immunostep, Salamanca, SP, EU) was used to detect PI- viable cells by flow cytometry. Absolute 
cell counts were obtained by the counting function of the MACSQuant Analyzer (Miltenyi Biotec). 
 
Western Blot analysis. Cell samples were washed in cold PBS and homogenized in RIPA buffer 
containing 1% Triton-X100, 0.2% BriJ, 1 mM sodium orthovanadate and protease inhibitors 
cocktail. Protein concentrations were determined using the Bradford protein assay (Bio-Rad 
Laboratories, Milano, Italy). Blotting analysis was performed using anti-AR, anti-phospho STAT3 
and anti-STAT3 antibodies (Santa Cruz Biotechnology); anti-phospho Akt, anti-phospho ERK1/2 
(Cell Signaling).  To normalize the amount of loaded proteins, all blots were probed with anti–
Tubulin antibody (Sigma). 
 
Heterotopic tumor model. Animal experiments were approved by the local animal ethics 
committee (OPBA, Organismo Preposto al Benessere degli Animali, Università degli Studi di 
Brescia, Italy) and were performed in accordance with national guidelines and regulations. Nine 
week-old C57BL/6 male mice were injected s.c. with 5x106 TRAMP-C2 cells in 200 µl total 
volume of PBS into the dorsolateral flank. When tumors were palpable (~80mm3), mice were 
divided in two groups and treated or not with enzalutamide (3 mg/kg) in the drinking water. 
Treatments with everolimus (1 mg/kg) were performed every other day i.p., and with cabazitaxel 
(15 mg/kg) i.p. every two weeks. Tumors were measured in two dimensions and tumor volume was 
calculated according to the formula V=(D x d2)/2, where D and d are the major and minor 
perpendicular tumor diameters, respectively [17]. At the end of the experimental procedure tumors 
were removed, weighted and processed for histological analyses. 
 
In vivo treatment of TRAMP mice. TRAMP mice (C57BL/6-Tg(TRAMP)8247Ng/J) [18] were 
purchased from The Jackson Laboratory (Bar Harbor, ME, USA), bred crossing homozygous 
females with C57BL/6J wild type males and heterozygous TRAMP males were used for 
experimental procedures. Treatment was carried out adding enzalutamide (3 mg/kg) in the drinking 
water and treated or untreated mice were sacrificed at different time points, as indicated in the 
Results section, to collect the genitourinary apparatus that was weighted and prepared for histology. 
Treatment with cabazitaxel (15 mg/kg) was performed i.p. every two weeks. 
 
Murine prostate histopathological analysis. The genitourinary apparatus was removed from wild-
type or TRAMP male mice (treated or not with enzalutamide) at different ages, formalin-fixed and 
paraffin-embedded. Anterior prostate samples were sectioned at a thickness of 7µm, dewaxed, 
hydrated, and stained with hematoxylin and eosin (H&E) or processed for immunohistochemistry. 
Sections stained with H&E were evaluated for specific histological abnormalities. The full prostate 
section was acquired at 20x magnification with a Zeiss Axiovert 200M microscope (Carl Zeiss, 
Milan, Italy, EU) using the “Mosaic Tool” and the quantification of the pathological areas was 
performed with the AxioVision LE64 software. Also, the number of pathological adenomeres was 
determined and pathological areas were graded as described [19]. 
For the Immunohistochemical analysis, prostate sections were incubated with rat anti-mouse Ki67 
antibodies (Dako, Milano, Italy, EU). Positive signal was revealed by 3,3'-diaminibenzidine 
(Roche) staining. Sections were finally counterstained with Mayer’s hematoxylin before analysis by 
light microscopy. Images were acquired at 10x magnification with a Zeiss Axiovert 200M 
microscope and Image analysis was carried out using the ImagePro Plus software.  
 
Statistical analyses. Statistical analyses were performed using the statistical package Prism 5 
(GraphPad Software). Student’s t test for unpaired data (2-tailed) was used to test the probability of 
significant differences between two groups of samples. Tumor volume data were statistically 
analyzed with a 2-way analysis of variance, and individual group comparisons were evaluated by 
the Bonferroni correction. Differences were considered significant when P < 0.05.	
 
Formulation and parameterization of the Mathematical model. 
The multiscale stochastic mathematical model presented in the quick guide describes PCa tumor 
cells dynamics in vivo and their response to treatment with enzalutamide.  Drug resistance is a well-
known issue in cancer patients’ treatment, and in the last few years, many mathematical models 
have been proposed to fully understand the dynamics of the resistance and to find effective 
therapeutic strategies to overcome it [20-22].  Recent experimental evidence suggests that tumor 
heterogeneity, tumor microenvironment and the ability of tumor cells to adapt to targeted therapy 
play a key role in the phenomenon of drug resistance [20, 23]. One of the consequences of 
heterogeneity is that within the same tumor there will be cells which are sensitive to drug therapy 
while others exhibit resistance to it [23], with this in mind we assumed that sensitive cells can 
undergo asymmetric cell division, resulting in resistant daughter cells. The development of the 
model was strongly led and supported by the experiments.  To link the in vitro and in vivo results 
we incorporated the dynamics of the local tumor microenvironment, and how it affects the fitness of 
sensitive and resistant tumor cells. This was done by adapting previously developed spatial models 
of tumor growth [24, 25]. Values of cell-growth related parameters were obtained through the 
fitting of the experimental data. The nonlinear regression of data from the cell proliferation assay 
provided the values for the maximum growth rate coefficients of sensitive and resistant cells 
respectively, r1=0.048 ± 0.009 hr-1 and r2=0.038 ± 0.003 hr-1 (Supplementary Mathematical Model). 
The inhibition parameters b1 = 0.064 ± 0.008 µM-1, b2 = 0.34 ± 0.3 and a2 = 5.63 ± 5 µM were 
estimated with data from the experiments on the effect of different concentrations of enzalutamide 
on cell growth in starving conditions (Supplementary Mathematical Model). The empiric function 
proposed by Casciari et al. [24] to describe the impact of nutrients (oxygen and glucose) and pH on 
cell growth was used as it is. Although, the parameters representing the maximum environmental 
inhibition (C0i, i=1,2) on cell growth were calibrated from fitting the in vivo cell growth data. 
Independent experiments showed that based on the concentration of enzalutamide in the 
environment, sensitive cells mutate into resistant cells and that the mutation is reversible. Such a 
phenomenon was modeled following the approach by Portz et al. [26] for the case of PCa cells 
treated with androgen deprivation therapies. Estimates of parameter values were obtained using 
independent experimental data (Supplementary Table S1). The equation for the pharmacokinetic of 
enzalutamide follows the one proposed by Sun et al. [22] for the dynamics of absorption, 
metabolism and elimination of a generic drug from the body.  When the experiments were not 
available the parameter values were collected from previous suitable studies [22, 24, 25].  More 
details on the parameterization can be found in the file Supplementary Mathematical Model.  
RESULTS 
Quick Guide to Equations and Assumptions. 
Here we present a system of five stochastic differential equations that describe the interaction 
between heterogeneous cancer cell populations, the pharmacokinetics of the administered drug and 
the dynamics of the tumor microenvironment. The development of the system is based on in vivo 
experiments on TRAMP mice, and in vitro experiments on TRAMP-C2 cells growing in a Petri 
dish. Most of the ideas presented in this model have been adapted from previous works on human 
PCa development [22, 27], and prostate tumor in TRAMP mice by Ibrahim-Hashim [25] and Picco 
[28].   
The model describes the growth of two populations of cancer cells: a drug sensitive population (S),  
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The growth of drug-sensitive and -resistant cells are represented by the first term of equation (E.1) 
and (E.2), respectively. The two tumor cell populations follow a logistic growth with K being the 
shared carrying capacity, and $% and $+ the growth rate coefficients of each cell type.  Cell 
proliferation is assumed to be dependent on oxygen and pH levels. At this purpose the empiric 
function proposed by Casciari et al. [24] was adapted and used to model the parameters  $% and $+: 
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The function fi assumes values in [0,1]	and represents the fraction of maximum growth that cells 
can achieve given a specific set of conditions. T_  (j=o, h) and n are empirical parameters, while the 
variables Q and H are respectively the oxygen and hydrogen ion concentration.   
The growth of the sensitive type cells is also assumed to be asymmetric, i.e., S cells can randomly 
divide into drug-resistant cells, with rate g.  As suggested by the in vitro experiments the 
administered drug induces death in both populations with different inhibition laws.  Following 
treatment, the drug-sensitive cells undergo drug-induced death following a mass action law with 
maximal death rate 45. On the other hand, drug-resistant cells undergo drug-induced death 
following drug administration too, but in this case the dependence of the death rate on the drug 
concentration (E) follows a Michaelis-Menten law, with 4O representing the maximal death rate, 
and `O representing the drug concentration at which the inhibition effect is half of its maximum 
(4O).  The presence of enzalutamide triggers a selective pressure on sensitive cells that consequently 
develop resistance to the drug with a rate ;+, e.g. through epigenetic mutations. The phenomenon is 
reversible and in an environment with a low or no enzalutamide concentration, resistant cells 
convert to sensitive cells with a rate ;%. In this last case S cells will likely stay sensitive.  The 








The R to S mutation rate, ;%, is assumed to be an increasing function of enzalutamide. The higher 
the drug concentration is in the environment the more cells developing resistance following 
selective pressure. On the other hand, the S to R mutation rate, ;+, is assumed to be a decreasing 
function of the drug concentration, that is, the less enzalutamide is in the environment the more R 
cells will mutate into sensitive type cells.  Both sensitive and resistant cells die with rate µ. The last 
diffusion terms in both equation (E.1) and (E.2) represent a standard Brownian motion, or standard 
Wiener process, which models the stochastic fluctuation of cell numbers. The Wiener process is 
described by the normally distributed random variable W(t), with mean zero and variance ∆t.  The 
parameters C9 (i = 1, 2) represent the diffusion rates. 
The dynamics of enzalutamide concentration in the body is represented by the following equation 
!6 = − ℎ	6	!-
EIf/@K@2908
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The drug degrades with a maximum rate h and is delivered with a time dependent rate V(t) defined 
by the therapy. As for the populations, also in this case a Wiener process describes the stochasticity 
of the system [29]. 
This model represents the metabolic behaviour of the cells as dependent on the micro-
environmental conditions, which are described by the two diffusible variables: oxygen (O) and 
extracellular pH modeled in terms of hydrogen ion concentration (H).  The drift functions for O and 
H are those suggested by Ibrahim-Hashim et al. [25] and Robertson-Tessi et al. [30].  A constant 
oxygen input is assumed to feed the extracellular (considered equal to intracellular) oxygen 
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Maximum oxygen consumption rates, V01 and V02 are characteristic of the cell type, sensitive and 
resistant cells respectively. According to Robertson-Tessi et al. proton dynamics depends on the 
amount of anaerobic glycolysis. A parameter n.  characterizes the cell type. Normal cells using an 
aerobic glycolysis would have n. = 1, while for tumor cells n. > 1 indicating that more glucose 

























.      (E.5) 
As in equations (E.1), (E.2) and (E.3), also in equations (E.4), and (E.5) D9 are Wiener processes 
with C9 (i = 4, 5) representing the diffusion rates. 
Additional equations and parameterization details are reported in the Supplementary Mathematical 
Model. 
 
Enzalutamide impairs murine prostate cancer cell growth in vitro and in vivo. 
TRAMP-C2 cells represent a prototypic murine androgen-dependent prostate cancer cell line 
derived from the multistage TRAMP mouse model. As shown in Figure 1A, a 4-day treatment with 
increasing concentrations of enzalutamide strongly reduced cell proliferation, with an IC50 ~24µM, 
with no induction of cell death (Supplementary Figure S1). Western blot analysis revealed that the 
proliferative impairment is accompanied by reduction of STAT3, AKT and ERK1/2 activation 
(Figure 1B). In agreement with other studies performed in human PCa cells [31], no significant 
reduction in AR protein levels was detectable after four days of treatment with enzalutamide 
(Figure 1B). 
To further assess the therapeutic potential of enzalutamide in vivo, TRAMP-C2 cells were injected 
subcutaneously in syngeneic male mice. When tumors reached a size equal to ~80mm3, mice were 
treated or not with 3 mg/kg of enzalutamide in the drinking water. As shown in Figure 1C-D, 
treatment with enzalutamide significantly delayed and reduced tumor volume, resulting in an 
impairment of tumor growth when compared to the control group. 
 
Enzalutamide delays tumor onset and progression in TRAMP mice. 
In the C57BL/6 background of the multistage TRAMP model, the age-dependent transformation of 
the prostate starts at 8-10 weeks with prostatic intraepithelial neoplasia (PIN) and progresses to well 
differentiated carcinoma and poorly differentiated adenocarcinoma [32]. The therapeutic potential 
of enzalutamide was tested in the TRAMP model by treating mice with 3 mg/kg of enzalutamide in 
the drinking water starting from 12 weeks of age, when tumor onset has already started. Then, 
animals were examined for prostate tumor growth at 18, 22, 25 and 30 weeks. 
As shown in Figure 2A, the weight of the genitourinary (GU) apparatus of TRAMP mice increases 
over time following tumor progression, reflecting tumor burden and organ oversizing/impairment. 
In enzalutamide-treated mice, the GU weight remains similar to that measured in healthy/wild type 
(WT) mice up to 22 weeks of age, starting to increase from week 25 and reaching the weight of the 
untreated TRAMP group at week 30.  
Figure 2B shows representative H&E pictures of anterior prostate sections from wild-type (WT), 
TRAMP and enzalutamide-treated TRAMP mice at 18, 25 and 30 weeks. As described, the anterior 
prostate of WT mice has a normal morphology with alveolar gland lined by cubic epithelium with 
finger-like projections and the cells containing typically central nuclei. At variance, we observed a 
progressive increase of pathological areas in TRAMP mice, characterized by neoplastic 
proliferation of epithelial cells with nuclear atypia (hyperchromatic elongated nuclei or 
heterochromatic round nuclei). Indeed, smallest cells appear in several layers, they tend to occupy 
the gland lumen, even though at this stage the glandular architecture is still present.  
In keeping with variations in the weight of the GU apparatus, histopathological analysis of the 
anterior prostate lobes revealed that the percentage of total pathological areas in untreated TRAMP 
mice increases from (17.4 ± 2.0)% at 12 weeks to (38.0 ± 3.9)% and (53.2 ± 3.7)% at 22 and 30 
weeks of age, respectively (Figure 2C). This was paralleled by a decrease of normal/healthy (NH) 
prostatic tissue, an increase of PIN areas until week 22 and of well-differentiated (WD) carcinoma 
areas up to week 30 (Figure 2D). At variance, the percentage of total, PIN and WD pathological 
areas remains stable in the enzalutamide-treated TRAMP group at 18 and 22 weeks, to increase 
significantly thereafter (Figure 2C-D).  
The early anti-tumor effect of enzalutamide observed at 18 weeks and the subsequent progressive 
transformation of TRAMP prostate occurring at week 25 was confirmed by the increase of 
proliferating/Ki67+ areas in enzalutamide-treated 25-week old mice (Figure 2E). Together, these 
data indicate that the inhibitory effect exerted by enzalutamide on TRAMP tumor progression is 
progressively lost from week 25 onward.  
 
Model prediction of tumor kinetics and onset of resistance following enzalutamide treatments. 
The in vitro and in vivo data where used to develop the mathematical model described in the quick 
guide, and allowed investigating the dynamics of sensitive (S) and resistant (R) cells in silico with 
and without enzalutamide treatment.  
As shown in Figure 3, the percentage of pathological area in the prostate of TRAMP mice (scattered 
dots) differently develops with time, in absence (A) and in presence (B) of enzalutamide continuous 
treatment. The mathematical model (blue continuous lines with 95% CI – orange and green 
continuous lines) recapitulates tumor growth, for instance ~94% of experimental observations fall 
in the 99.8% of the model simulations. The percentage of pathological area was calculated 
assuming that the maximum was reached at a volume of 1000 mm3. The value was calculated from 
the estimated carrying capacity, K, by assuming a standard deviation of approximately 20% of K. 
Moreover, in silico prediction of the time course of tumor distributions show that the tumor 
increases constantly in time in the absence of treatment. From week 22, the tumor distribution 
reaches its maximum at around 500/600 mm3 (Figure 3C). In the presence of enzalutamide 
treatment, the distribution is almost unchanged between week 12 and week 22, with a slight 
improvement at 18 weeks. However, the distribution shows that the tumor volume starts to increase 
at week 25 to continue in the following weeks (Figure 3D). Such behavior reflects the experimental 
evidence shown in Figure 2B.  
The model suggests that untreated/control tumors are dominated by the growth dynamics of S cells, 
while enzalutamide-treated tumors are dominated by the switch from S to R cells and consequently 
by the dynamics of R cells.  
Drug-induced mutation/transition, in the absence and in the presence of enzalutamide, is shown in 
terms of the dynamics of the proportion of S and R cells (dotted and continuous lines, respectively 
in Figure 4A-B and in Supplementary Figure S2). On the contrary, in the presence of enzalutamide 
(Figure 4B), R cells arise and become the dominant population soon after the beginning of the 
treatment. This is explained by the fact that the inhospitable tumor microenvironment is 
characterized by increased acidity (with the pH varying from an initial value of 7.2 to a value in the 
range of 6.5 to 7.0), and a sensible decrease in oxygen (minimum 1.5%) while S cells invade the 
prostate (Supplementary Figure S3). In this more hostile context, drug-resistant cells have a fitness 
advantage when compared to their drug-sensitive parental cells, and this is not only due to the drug 
sensitivity and/or to the different mechanisms by which the drug acts on the cells, but also to the 
more effective way R cells respond to hypoxia and acidosis. Indeed, the reduction in growth of the 
R cells in the inhospitable environment is in fact less than half the reduction calculated for S cells.   
In the attempt to find a “therapeutic window”, our model was applied to evaluate in silico the 
cellular response to different treatment schedules with enzalutamide. The main aim was to decrease 
the number of S cells while avoiding the emergence of R cells. Three in silico experiments were 
performed, varying the dose and timing of enzalutamide administration, with no significant 
improvement in the therapeutic outcome (Figure 4C-E). In most of the conditions evaluated it was 
possible to control the growth of S cells, but not relevant effect was observed in the emergence of R 
cells that will dominate tumor growth (Figure 4C-E). A possible explanation is that even though 
high levels of enzalutamide are able to kill S cells, they cause a strong “metagenetic” response, with 
S cells mutating into the R type, which is capable of proliferating despite the adverse environmental 
conditions.  In silico experiments also showed that, due to the heterogeneous nature of cancer cells, 
which implies that cells might develop some kind of resistance even in absence of enzalutamide, the 
use of lower levels of enzalutamide will not prevent the appearance of high fitness resistant cells 
and tumor relapse. 
 
Enzalutamide-resistant TRAMP-C2 cells show CRPC markers and metabolic fitness 
In order to mimic and better understand the emergence of enzalutamide resistance in vivo, we 
generated an enzalutamide-resistant cell line by culturing TRAMP-C2 cells in media gradually 
enriched with increasing concentrations of the drug (from 3µM to 40µM) up to 6 months. These 
resistant cells did not show morphological changes when compared to their aged-matched parental 
cells (Figure 5A). As evidence of the acquisition of enzalutamide-resistance features, qPCR analysis 
revealed a significant up-regulation of full-length AR mRNA and a strong down-modulation of 
TMEFF2 [33] and TMPRSS2 [34], two crucial modulators of the castration-resistant status in PCa 
[35] (Figure 5B). These data suggest that TRAMP-C2 cells efficiently overcome the ligand 
deficiency conferred by long-term enzalutamide treatment by elevating AR levels and decreasing 
androgen-dependent genes exerting anti-proliferative effects. Accordingly, enzalutamide-resistant 
TRAMP-C2 cells showed an increased IC50 (83µM) following an acute enzalutamide treatment 
when compared to aged-matched parental cells IC50 (24µM) (Figure 5C).  
The in vitro characterization of enzalutamide-resistant TRAMP-C2 revealed that these cells were 
endowed with a reduced proliferative rate compared with their parental counterpart (Supplementary 
Mathematical Model). On the other hand, the mathematical model suggested that R cells appear to 
be much more efficient in dealing with oxygen deprived and lower pH conditions when grown in 
vivo, showing a higher fitness than S cells.  For this reason, we further characterized enzalutamide-
treated cells by measuring their main metabolic pathways with Seahorse analyzer. In particular, 
mitochondrial oxidative phosphorylation and glycolysis were measured simultaneously via OCR 
(oxygen consumption rate) and ECAR (extracellular acidification rate). The energy map based on 
extracellular flux analysis (Figure 5D) showed that enzalutamide-resistant cells have altered 
mitochondrial bioenergetics as indicated by reduction of oxidative phosphorylation and a distinct 
acidic phenotype, as indicated by their increased glycolysis capacity.  
These findings are in keeping with the NMR-based metabolomics analysis that revealed 
conspicuous differences in metabolic profile between enzalutamide-resistant cells and their parental 
aged-matched cells (Figure 5E). Spectra acquisition show some hydrophilic signals commonly 
identified as hallmark of castration resistant cell secretion, such as pyruvate and lactate, highly up 
regulated in resistant cells and indicating high glucose consumption (enhanced glycolysis) and 
hyper-acidosis. Metabolite analysis in resistant cells also indicated a lower ATP production and 
augmented levels of alanine, glycine, and other amino acids, indicating propensity in synthesizing 
amino acids. Moreover, the levels of several substrates used in TCA cycle by different mitochondria 
complexes, such as glutamate and succinate, were up regulated in resistant cells, thus indicating a 
reduced use of oxidative phosphorylation to produce energy in this phenotype. 
Overall, these data were consistent with the topology-based pathway analysis, which indicated the 
metabolic networks potentially affected during the transition of TRAMP-C2 cells from an 
enzalutamide-sensitive to a resistant phenotype. As shown in Figure 5F, the most impacted 
metabolic pathways were related to alanine, aspartate and glutamate metabolism as specified by the 
volume and the color of the spheres (yellow, least relevant; red, most relevant) according to their 
statistical relevance P and impact value.  
 
Model prediction and evaluation of enzalutamide-based combination therapies. 
In order to overcome resistance to enzalutamide treatment we implemented the mathematical model 
to evaluate the effect of two clinically relevant drugs: everolimus, an mTOR inhibitor currently in 
clinical trial in combination with second-generation AR inhibitors [36], and cabazitaxel, a next-
generation taxane approved for the treatment of metastatic CRPC in patients previously treated with 
docetaxel [37]. In vitro proliferation assays performed on parental and enzalutamide-resistant 
TRAMP-C2 cells were used to determine the IC50 and the dose response of both everolimus and 
cabazitaxel alone or in combination with enzalutamide (Figure 6A-D). 
These data were used for the parametrization of the enriched mathematical model where both the 
equations of the new-drugs pharmacokinetic, and the interaction between enzalutamide and the two 
new drugs were considered (details in the Supplementary Mathematical Model). The model was run 
for the simulation of in vivo tumor growth under treatment with enzalutamide, everolimus and 
cabazitaxel. The parameterization concerned the new functions and equations, while all other 
parameters stayed as previously evaluated.  As shown in Figure 6E-F, treatment with enzalutamide 
plus cabazitaxel was expected to have a higher impact in delaying tumor growth, resulting in 
smaller tumors at the latest volume point considered for the simulation (>70 days). 
We therefore validated the in silico drug combination to overcome the resistance to enzalutamide in 
vivo. An in vivo challenge on s.c. injected TRAMP-C2 cells confirmed that treatment with 
everolimus alone or in combination with enzalutamide resulted in no significant improvement in 
terms of anti-tumor activity when compared with enzalutamide given as single agent (Figure 7A). 
Interestingly, in agreement with the stochastic model simulation, treatment with cabazitaxel alone 
significantly delayed tumor growth when compared with enzalutamide, and the combination 
enzalutamide plus cabazitaxel emerged as the most effective therapeutic setting (Figure 7B).  
As a proof of concept, the experimental tumor growth curves (represented by dots in Figure 6E-F) 
fall into the confidence intervals of the simulation in both combination treatments, revealing and 
confirming that enzalutamide plus cabazitaxel represents the best performing approach able to 
longer control tumor growth. 
Prompted by the encouraging result obtained in silico and in vivo, we also run the simulation on the 
multistage tumor growth of TRAMP mice to predict the impact of the treatment on the evolution of 
the pathology. The model suggested that an in vivo enzalutamide plus cabazitaxel therapy would be 
successful in eliminating the tumor within 40 weeks (Figure 7C and Supplementary Figure S4).  On 
this basis, TRAMP mice were treated with enzalutamide and cabazitaxel in single or combination 
regimens. As shown in Figure 7D, the enzalutamide plus cabazitaxel therapy exerted a significant 
impact on tumor growth, as assessed at the later time point considered (30 weeks), compared to 
single agent treatment. Accordingly, histopathological analysis (and GU/body weight ratio; 
Supplementary Figure S5) confirmed a significant impact of the combination regimen on tumor 
progression, resulting in very low (or no) pathological areas at the end of the experimental 
procedure (Figure 7D).  Finally, a sensitivity analysis performed on several parameters revealed 
that, depending on the considered drug combination, the system’s behavior is more robust, in terms 
of the effect of the drug interaction, on either R or S cells. For each of the two introduced drugs the 
sensitive parameters would mostly refer to only one of the two phenotypes, and particularly to S 
cells for cabazitaxel and to R cells for everolimus (see Supplementary Figure S5 and Supplementary 
Mathematical Model).   
DISCUSSION 
As a leading cause of morbidity and mortality in men, prostate cancer has been widely studied and 
characterized in preclinical settings in order to bring therapeutic benefits to patients. Despite a first 
line response to canonical ADT and other new treatments, androgen independent tumors arise 
frequently with bad prognosis and poor therapeutic alternatives.  
In this study, we characterized the full-time course of prostate tumors in response to enzalutamide 
taking advantage of the genetic murine TRAMP multistage model of PCa and related TRAMP-C2 
cells in vitro and in vivo. Treatment with enzalutamide shows a significant effect on TRAMP-C2 
cells both when cultured in vitro and when injected subcutaneously in syngeneic mice. Moreover, 
the therapeutic profile of enzalutamide-treated multistage TRAMP mice reveals that tumor 
progression is initially arrested for a significant time period (up to week 22 of age), when the 
percentage of pathological areas measured in the anterior prostate lobe is similar to that detectable 
in untreated TRAMP animals at week 12. Mirroring what happens in the clinics [13], long term 
administration of the drug resulted in the generation of enzalutamide-resistant TRAMP-C2 cells in 
vitro, and in the occurrence of tumor relapse both in subcutaneous TRAMP-C2 grafts and in 
multistage TRAMP mice in vivo. Indeed, TRAMP-C2 tumors start growing in vivo after a 
significant first line response. The amount of pathological areas in the prostate of TRAMP mice 
starts to increase at week 25, which represents the main “relapse time point” to be considered in 
enzalutamide-treatment experiments.  
In a translational perspective, these TRAMP-integrated models represent a potential syngeneic 
platform to investigate the evolution of a therapeutic response to PCa and CRPC. Initial success and 
relapse are anticipated outcomes that resemble the clinical setting of PCa during its treatment. 
Different mechanisms have been found to be responsible for tumor progression after treatment with 
enzalutamide in murine and human models [38, 39]. AR alterations leading to androgen-
independent activation, such as the AR-V7 variant [40] and the F876L mutant [41], have been 
identified and characterized in patients with progressive disease. Increase of glucocorticoid receptor 
and transcription factors involved in the regulation of epithelial to mesenchymal transition (i.e. 
Twist and Snail) have also been described in human PCa cells treated with enzalutamide [42, 43]. 
Other bypassing mechanisms, including activation of PI3K/AKT pathway [44], increase of intra-
tumor androgen biosynthesis through overexpression of AKR1C3 [45], or neuroendocrine/lineage 
switching following TP53 and RB1 alterations [46] have been associated with resistance to 
enzalutamide. 
Notably, independently of the specific mechanism leading to resistance, in this work all data 
collected during in vitro and in vivo experiments were used for the first time to build a solid 
parametrization of growth conditions of PCa cells in the presence or absence of the therapeutic 
drug. Mathematical modeling of tumor behavior represents a seldom exploited, but extremely 
powerful and promising approach to investigate, and possibly predict, cancer ongoing and response 
in preclinical and clinical settings [47]. Studies conducted on PCa, colorectal and ovarian cancer 
(just to mention some of them) proved that by integrating empirical data with a mathematical 
framework of tumor growth it is possible to gain insights into the dynamics of intratumoral 
evolution [25, 26]; predict the effect of different combinations of drugs on patient survival rate [22, 
48]; forecast the progression of the disease and develop personal adaptive therapeutic strategies 
[49]; and understand what strategies will be the most effective ones in controlling tumor growth 
[50]. 
Here, the mathematical analysis of tumor response describes how the number of drug-sensitive cells 
in pathological prostate adenomers decreases over time under enzalutamide-treatment conditions, 
while resistant cells outgrow and emerge as the predominant population. The numerical simulation 
nicely shows that this tendency is maintained over time in a high number (up to 1000) of 
realizations of the model, and regardless of the treatment schedule. Despite its first line efficacy, an 
enzalutamide-resistant cell subpopulation emerges and will emerge under different conditions.  The 
mathematical model also shows how even if resistant cells exhibit a low rate of growth in vitro, they 
display a much higher fitness than their sensitive parental cells when grown in vivo under 
suboptimal nutrient and pH conditions. This agrees with the major metabolic perturbations in amino 
acid metabolism and sugar-associated pathways observed in enzalutamide-resistant cells. In 
particular, resistant cells are endowed with increased levels of glutamate, succinate, alanine, 
glycine, taurine, pyruvate and lactate, while other metabolites, such as glutathione, UDP-N-
acetylglucosamine and ATP, were down regulated in respect to their aged-matched parental cells. 
Moreover, the implementation of the stochastic model allowed the evaluation of combination 
strategies aimed to overcome resistance or to improve the therapeutic profile/response. As a proof 
of concept, clinically relevant drugs (i.e. everolimus and cabazitaxel) resulted in different benefits 
in terms of anti-tumor activity, when combined with enzalutamide, and the mathematical simulation 
nicely predicted these experimental findings. For instance, in accordance with recently published 
clinical data, cabazitaxel alone showed a promising therapeutic profile [37], and the still unexplored 
combination enzalutamide plus cabazitaxel resulted as the best therapeutic setting to prolong 
survival and impact on tumor growth on both s.c. and multistage PCa models.  
Interestingly, the interpretation of the sensitivity analysis results revealed that in combined 
treatments with enzalutamide (and bona fide with other drug candidates) the most sensitive 
parameters, which decide the outcome of the tumor growth, are the drug administered dose and the 
parameters representing the efficacy of the drug combination on either cell phenotype. Moreover, 
what emerged from this study is that no single parameter is reliably able to predict combination 
effects, and that to predict the therapeutic effect or the delay of tumor relapse it is necessary to 
focus on the combined effect of the interacting drugs (i.e. enzalutamide-cabazitaxel) on resistant 
cells. This aspect is of crucial importance and should be considered to screen and evaluate candidate 
drugs to be associated with enzalutamide or other first line therapies for the treatment of PCa and 
CRPC.  
In conclusion, we implemented an integrated syngeneic “TRAMP-based platform” (see Graphical 
Abstract), widely exploited as a useful model to study PCa, by generating in vitro and in vivo 
enzalutamide-resistant cells, and by describing the evolution of PCa in response to second-
generation AR signaling blocker with a stochastic multiscale mathematical model. The outcome 
represents a powerful tool to test and validate new drugs to be used in combination with 
enzalutamide for the treatment of PCa and CRPC. The mathematical model described in this work 
can be used effectively to predict and validate the response of new drugs in PCa as well as to 
envision combination treatments following collection of new in vitro and in vivo evidence. Also, 
following existing approaches [22] the model can be easily integrated to account for the dynamics 
of multiple drugs and of metastatic cells.  Once again, this study confirms that combination 
therapies remain the unmet strategy to be pursued in PCa treatment to avoid relapse and lethal 
progression of the disease. Future integrations of this mathematical model with clinical data from 
PCa patients and combination therapy parameters/equations could predict/evaluate the best 
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FIGURE LEGENDS 
Figure 1. TRAMP-C2 cell response to enzalutamide in vitro and in vivo. 
Cell proliferation (A) and Western blot analysis (B) on TRAMP-C2 cells treated with increasing 
concentrations of enzalutamide (Enza). DMSO was used as control, NT= not treated.  C) In vivo 
tumor growth (pictures and tumor weight at the explant, in D) of subcutaneous TRAMP-C2 tumors. 
The arrow indicates treatment start (continuous oral administration); data are the mean ± SEM of 8-
10 tumors/group; ** P<0.01, *** P<0.001). 
 
Figure 2. Effect of enzalutamide in TRAMP mice. 
A) Wild type (WT), TRAMP and enzalutamide-treated TRAMP mice were sacrificed at different 
time points (12, 18, 22, 25 and 30 weeks) and the genitourinary to body weight ratio determined. B) 
Representative picture (H&E) of anterior prostate lobes of Wild type, TRAMP and enzalutamide-
treated TRAMP mice at 18, 25 and 30 weeks (scale bar: 100µm). C) Quantification (percentage) of 
the pathological area in the anterior prostate of TRAMP mice treated (+Enza) or not with 
enzalutamide. D) Histopathological evaluation of prostate tissue after explantation; the graph shows 
the percentage of normal healthy tissue (NH, in grey), prostatic intraepithelial neoplasia (PIN, in 
green) and well differentiated tumor area (WD, in white) in the prostate of untreated (-) or treated 
(+E) TRAMP mice. E) Representative pictures and quantification of Ki67+ areas in prostate 
adenomers at 18 and 25 weeks (scale bar: 50µm). Data are the mean ± SEM; n= 8 or more 
animals/group; *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 3. Numerical simulations and time course of tumor distribution. 
Plots A and B show how the percentage of pathological area in the prostate develops with time, in 
absence (A) and in presence (B) of enzalutamide continuous treatment. Starting from above the 
continuous lines represent the upper bound of the 3σ confidence interval (CI), the mean, and the 
lower bound of the CI of all model realizations given the parameter values in Table S1. All points 
represent experimental data. Plots Ca and Da show 1000 realizations of the dynamics of 
enzalutamide-sensitive and -resistant tumor cells in time, described by the stochastic equations (E.1) 
and (E.2), in absence and presence of enzalutamide treatment respectively.  Plots C(b-f) and D(b-f) 
represent the tumor distributions for the 1000 realizations in absence (A plots) and presence (B 
plots) of treatment at 12, 18, 22, 25 and 30 weeks.   
 
Figure 4. Model of resistant cells onset and in silico simulation of enzalutamide treatment 
schedules. 
Plots A and B show the behavior of the proportion of sensitive (dotted lines) and resistant cells 
(continuous lines) in absence (A) and presence (B) of enzalutamide over time. C-E) In silico 
experiments showing the effects on R (i=3) and S (i=2) cells number of three enzalutamide 
treatments (i=1). In Ci (i=1,2,3) increasing doses of enzalutamide (per week) are administered daily 
for 1 week followed by 2 weeks off.  In Di (i=1,2,3) enzalutamide is administered daily for 2 weeks 
followed by 4 weeks off, with a higher dose during the first week. In Ei (i=1,2,3) enzalutamide is 
administered daily for 3 weeks followed by 3 weeks off with equal doses for each week.  
 
Figure 5. Validation of enzalutamide resistance acquisition in TRAMPC2 cells. 
A) Bright field microscopy images showing cell morphology of parental and enzalutamide-resistant 
TRAMP-C2 cells (magnification: 400X and 200X). B) qPCR analysis of the genes driving 
androgen deprivation resistance in enzalutamide-resistant cells (AR-FL: Androgen Receptor full-
length, TMEFF2: Tomoregulin-2, TMPRSS2: transmembrane serine protease; *p <0.05, **p<0.01; 
t-test). C) Cell proliferation response of parental and enzalutamide-resistant TRAMP-C2 cells to 
increasing concentrations of enzalutamide. Data are shown as mean ± SEM of 3 independent 
experiments. D) Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) 
were determined using the Seahorse XF96 Analyzer in TRAMPC2 and enzalutamide-resistant cells. 
Data are represented as the mean ± SEM (n=24).  E) S-line plot generated by multivariate data 
analysis of the NMR spectra. Metabolic changes in enzalutamide-resistant cells compared with 
parental cells are shown in blue as the least significant changes and in red as the most significant. F) 
Topology-based pathway analysis showing metabolic networks mainly affected in enzalutamide-
resistant cells according to their statistical relevance P and impact value. 
 
Figure 6. Simulations of drug combinations to overcome resistance to enzalutamide. 
In vitro cell proliferation assay performed on TRAMP-C2 parental or TRAMP-C2 enzalutamide-
resistant cells to test everolimus (A), everolimus in combination with enzalutamide (B), or 
cabazitaxel alone (C) and in combination with enzalutamide (D). In silico simulation of 
enzalutamide plus everolimus (E) and enzalutamide plus cabazitaxel (F). 
 
Figure 7. Validation of the in silico drug combinations to overcome the resistance to 
enzalutamide in vivo. 
In vivo tumor growth of subcutaneous TRAMP-C2 tumors treated with enzalutamide plus 
everolimus (A) and enzalutamide plus cabazitaxel (B). Data are the mean ± SEM of 8-10 
tumors/group). C) In silico simulation of tumor progression in TRAMP mice. D) In vivo: 
quantification (percentage) of the pathological area in the anterior prostate of TRAMP mice (at 30 
weeks of age) treated with the indicated drugs and combination. * P<0.05, ** P<0.01, **** 
P<0.0001).  
 
	







